Bayer plans to beef up biotech pipeline

Bayer Healthcare says it will aggressively expand its biotech pipeline in the year ahead, concentrating on new development pacts in cardiology, hematology and oncology. The company is looking to strike new deals similar to the ones it has reached with Nuvelo and Onyx Pharmaceuticals. Hans Bishop, the former senior v.p. for Chiron's UK operations, will likely head up many of these new ventures. Bishop is expected to be tapped as the next president of the company's hematology and cardiology business after Joe Akers retires.

- here's the report on Bayer from the East Bay Business Journal

Related Articles:
Bayer sells subsidiary in €1.2B deal. Report
Bayer Schering outlines global R&D restructuring. Report
Bayer outbids Merck KGaA for Schering. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.